NASDAQ:SLXN Silexion Therapeutics (SLXN) Stock Price, News & Analysis $0.94 -0.05 (-5.05%) Closing price 03:55 PM EasternExtended Trading$0.94 +0.01 (+0.53%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock About Silexion Therapeutics Stock (NASDAQ:SLXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Silexion Therapeutics alerts:Sign Up Key Stats Today's Range$0.92▼$0.9950-Day Range$0.58▼$3.1452-Week Range$0.58▼$41.85Volume200,494 shsAverage Volume5.85 million shsMarket Capitalization$7.91 millionP/E RatioN/ADividend YieldN/APrice Target$5.00Consensus RatingBuy Company OverviewSilexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.Read More… Remove Ads Receive SLXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Silexion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address SLXN Stock News HeadlinesSilexion Therapeutics (NASDAQ:SLXN) & Apogee Therapeutics (NASDAQ:APGE) Head-To-Head ComparisonApril 3 at 1:51 AM | americanbankingnews.comSilexion Therapeutics announces expanded development plan for SIL204March 28, 2025 | markets.businessinsider.comTrump to redistribute trillions of dollars Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 3, 2025 | Porter & Company (Ad)Silexion Therapeutics Unveils Innovative Expanded Development Plan for SIL204 Based on Recent Groundbreaking Preclinical DataMarch 28, 2025 | globenewswire.comSilexion announces completion of expanded development plan for SIL204March 21, 2025 | markets.businessinsider.comSilexion Therapeutics price target lowered to $5 from $9 at MaximMarch 21, 2025 | markets.businessinsider.comSilexion Therapeutics Announces Completion of Innovative Expanded Development Plan for SIL204 which will be unveiled at the 2025 NeauxCancer ConferenceMarch 21, 2025 | globenewswire.comSilexion Therapeutics Corp: Silexion Therapeutics Reports Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | finanznachrichten.deSee More Headlines SLXN Stock Analysis - Frequently Asked Questions How have SLXN shares performed this year? Silexion Therapeutics' stock was trading at $2.01 on January 1st, 2025. Since then, SLXN stock has decreased by 53.2% and is now trading at $0.94. View the best growth stocks for 2025 here. When did Silexion Therapeutics' stock split? Silexion Therapeutics shares reverse split on the morning of Friday, November 29th 2024. The 1-9 reverse split was announced on Saturday, January 1st 2000. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, November 28th 2024. An investor that had 100 shares of stock prior to the reverse split would have 11 shares after the split. How do I buy shares of Silexion Therapeutics? Shares of SLXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Silexion Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Silexion Therapeutics investors own include Arch Capital Group (ACGL), Adobe (ADBE), Analog Devices (ADI), Alnylam Pharmaceuticals (ALNY), Amgen (AMGN), AstraZeneca (AZN) and Baidu (BIDU). Company Calendar Today4/03/2025Next Earnings (Estimated)5/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SLXN Previous SymbolNASDAQ:SLXN CIK2022416 Websilexion.com Phone972-2-674-3430Fax212-572-6395EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$5.00 High Stock Price Target$5.00 Low Stock Price Target$5.00 Potential Upside/Downside+431.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$260,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-249.43% Debt Debt-to-Equity RatioN/A Current Ratio0.85 Quick Ratio0.85 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.64 per share Price / Cash Flow1.46 Book Value($6.63) per share Price / Book-0.14Miscellaneous Outstanding Shares8,415,000Free Float1,074,000Market Cap$7.91 million OptionableN/A Beta0.11 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:SLXN) was last updated on 4/3/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredNew “Trump” currency proposed in DCAfter a massive run-up – tech stocks are crashing. And as you’d suspect, the rich and powerful got out firs...Paradigm Press | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredTrump’s Secret WeaponPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredTrump Makes Major Crypto AnnouncementTrump Ends the “War on Crypto” I expect it to pump the market, which is why I'm recommending ONE coin to al...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Silexion Therapeutics Corp Please log in to your account or sign up in order to add this asset to your watchlist. Share Silexion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.